Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)

Hepatocellular carcinoma (HCC) remains a significant clinical challenge with few therapeutic options. Genomic amplification and/or overexpression of the MYC oncogene is a common molecular event in HCC, thus making it an attractive target for drug therapy. Unfortunately, currently there are no direct...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Dhanasekaran, Renumathy, Gabay-Ryan, Meital, Baylot, Virginie, Lai, Ian, Mosley, Adriane, Huang, Xinqiang, Zabludoff, Sonya, Li, Jian, Kaimal, Vivek, Karmali, Priya, Felsher, Dean W.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Priority Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814155/
https://ncbi.nlm.nih.gov/pubmed/29464015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22342
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items